TY - JOUR
T1 - Induction of anterior chamber-associated immune deviation requires an intact, functional spleen
AU - Streilein, J. Wayne
AU - Niederkorn, Jerry Y.
N1 - Funding Information:
∗Supported in part by grant EY 01330 from the U. S. Public Health Service, and a grant from the National Society to Prevent Blindness. 1Abbreviations used in this paper: ACAID, anterior chamber-associated immune deviation; HBSS, Hanks’ balanced salt solution; IC, intracameral; SC, subcutaneous.
PY - 2007/5
Y1 - 2007/5
N2 - Anterior chamber-associated immune deviation (ACAID) expresses itself in BALB/c mice inoculated intracamerally with P815 cells in three ways: progressive growth of the tumor within the eye, transient growth of P815 cells injected subcutaneously, and prolonged acceptance of DBA/2 skin allografts. The spleen was found to play a crucial role in the development of ACAID. Splenectomized animals bearing intracameral P815 tumors reject DBA/2 skin grafts in an accelerated manner. A functioning spleen was required during the first 10 d after intracameral inoculation of P815 cells, but not thereafter. Reconstitution experiments revealed that the spleen's ability to support the induction of ACAID depends partly upon its constituent lymphoid cells, but also upon either a stromal component or a unique architectural arrangement that can only be restored with splenic fragments. The data hold promise that therapeutic protocols using appropriately timed splenectomy and specific immunization can be devised to induce hosts bearing intraocular tumors to mount an immune response sufficiently vigorous to destroy the tumor within the eye, and sufficiently precise to preserve the functional and anatomic integrity of the eye.
AB - Anterior chamber-associated immune deviation (ACAID) expresses itself in BALB/c mice inoculated intracamerally with P815 cells in three ways: progressive growth of the tumor within the eye, transient growth of P815 cells injected subcutaneously, and prolonged acceptance of DBA/2 skin allografts. The spleen was found to play a crucial role in the development of ACAID. Splenectomized animals bearing intracameral P815 tumors reject DBA/2 skin grafts in an accelerated manner. A functioning spleen was required during the first 10 d after intracameral inoculation of P815 cells, but not thereafter. Reconstitution experiments revealed that the spleen's ability to support the induction of ACAID depends partly upon its constituent lymphoid cells, but also upon either a stromal component or a unique architectural arrangement that can only be restored with splenic fragments. The data hold promise that therapeutic protocols using appropriately timed splenectomy and specific immunization can be devised to induce hosts bearing intraocular tumors to mount an immune response sufficiently vigorous to destroy the tumor within the eye, and sufficiently precise to preserve the functional and anatomic integrity of the eye.
UR - http://www.scopus.com/inward/record.url?scp=35748935126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35748935126&partnerID=8YFLogxK
U2 - 10.1080/09273940701382473
DO - 10.1080/09273940701382473
M3 - Article
C2 - 17613833
AN - SCOPUS:35748935126
SN - 0927-3948
VL - 15
SP - 187
EP - 194
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 3
ER -